SFC/ALFEDIAM guidelines on the management of the diabetic patient seen by a cardiologist;Recommandations SFC/ALFEDIAM sur la prise en charge du patient diabétique vu par le cardiologue

Archives des Maladies du Coeur et des Vaisseaux

Volumn 97, Issue 3, 2004, Pages 229-249

  Charbonnel, B ^a   Bouhanick, B ^a,a   Le Feuvre, C ^a,a   Bauduceau, B ^a   Danchin, N ^a   Gautier, J F ^a   Grimaldi, A ^a   Henry, P ^a   Paillard, F ^a   Pallo, D ^a   Piot, C ^a   Sabouret, P ^a  

^a ALFEDIAM ^*

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACETYLSALICYLIC ACID; ALPHA GLUCOSIDASE INHIBITOR; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CLOPIDOGREL; DIHYDROPYRIDINE DERIVATIVE; DIURETIC AGENT; GLIBENCLAMIDE; GLICLAZIDE; GLIMEPIRIDE; GLIPIZIDE; GLUCOSE; HEMOGLOBIN A1C; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; INSULIN SENSITIZING AGENT; METFORMIN; METFORMIN EMBONATE; MIGLITOL; NITRENDIPINE; ORAL ANTIDIABETIC AGENT; PIOGLITAZONE; REPAGLINIDE; ROSIGLITAZONE; SIMVASTATIN; SULFANILAMIDE DERIVATIVE; THIAZIDE DIURETIC AGENT; UNINDEXED DRUG;

AGING; ANTICOAGULANT THERAPY; ANTIHYPERTENSIVE THERAPY; BLEEDING; BLOOD GLUCOSE MONITORING; BRAIN PROTECTION; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; DIABETES MELLITUS; DIABETIC ANGIOPATHY; DIABETIC NEPHROPATHY; DIET THERAPY; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG MECHANISM; DYSLIPIDEMIA; EXERCISE; GLUCOSE BLOOD LEVEL; HEART FAILURE; HEART MUSCLE ISCHEMIA; HUMAN; HYPERTENSION; INSULIN TREATMENT; KIDNEY FAILURE; LACTIC ACIDOSIS; METABOLIC SYNDROME X; MICROALBUMINURIA; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; REVIEW; RISK FACTOR; SMOKING;

ADULT; AGED; BLOOD GLUCOSE; BLOOD GLUCOSE SELF-MONITORING; CARDIOLOGY; COMORBIDITY; DIABETES COMPLICATIONS; DIABETES MELLITUS; FEMALE; FRANCE; GLUCOSE TOLERANCE TEST; HEART DISEASES; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERLIPIDEMIAS; HYPERTENSION; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MIDDLE AGED; REFERRAL AND CONSULTATION; RISK FACTORS;

EID: 12144290709     PISSN: 00039683     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (77)

1. nd ed. Bethesda, Md: National Institute of Health; 1995: 429-448. NIH publication 95-1468.
2. Saydah SH, Eberhardt MS, Loria CM, Brancati FL. Age and the burden of death attributable to diabetes in the United States. Am J Epidemiol 2002; 156: 714-9.
3. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in non-diabetic subjects with and without prior history of myocardial infarction. N Engl J Med 1998; 339: 229-34.
4. Evans JMM, Wang J, Morris AD. Comparison of cardiovascular risk between patients with type 2 diabetes and those who had had a myocardial infarction: cross sectional and cohort study. BMJ 2002; 324: 939-42.
5. Sprafka JM, Burke GI, Folsom AR, Mc Govern PG, Hahn LP. Trends in prevalence of diabetes mellitus in patients with myocardial infarction and effect of diabetes on survival: the Minnesota Heart Survey. Diabetes Care 1991; 14: 537-43.
6. ANAES. Suivi du patient diabétique de type 2 à l'exclusion du suivi des complications: recommandations de l'ANAES. Diabetes Metab 2000; 25 (Suppl. 2): 1-64.
7. Norhammar A, Tenerz A, Nilsson G et al. Glucose metabolism in patients with acute myocardial infarction and noprevious diagnosis of diabetes mellitus: a prospective study. Lancet 2002; 359: 2140-4.
8. Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in adults. Executive summary of the third report of the National Cholesterol Education program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in adults (adult treatment panal III). JAMA 2001; 285: 2486-97.
9. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Follow up report on the diaqnosis of Diabetes Mellitus. Diabetes Care 2003; 26: 3160-7.
10. Richard LD, Sultan A, Daures JP, Vannereau D, Parer-Richard C. Diagnosis of diabetes mellitus and intermediate glucose abnomalities in obese patients based on ADA (1997) and WHO (1985) criteria. Diabetes Metab 2002; 19: 292-9.
11. The Expert Committee on the Diagnosis and classification of diabetes mellitus. Diabetes Care 1997; 20: 1183-97.
12. Girard J. Fondements physiopathologiques du diabète de type 2. Rev Prat 1999; 49: 22-9.
13. Kahn SE. The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of type 2 diabetes. Diabetologia 2003; 46: 3-19.
14. American Diabetes Association. Screening for diabetes. Diabetes Care 2003; 26 (Suppl. 1): S21-S24.
15. Abedin M, McGuire DK. Don't miss the opportunity: diagnosing diabetes. Am Heart J 2003; 145: 195-7.
16. Taubert G, Winkelmann BR, Qchleiffer T et al. Prevalence, predictors and consequences of unrecognized diabetes mellitus in 3266 patients scheduled for coronary angiography. Am J Heart 2003; 145: 285-91.
17. Heilbronn LK, Noakes M, Clifton PM. Effects of energy restriction, weight loss, and diet composition on plasma lipids, and glucose in patients with type 2 diabetes. Diabetes Care 1999; 22: 889-95.
18. Boule NG, Haddad E, Kenny GP, Wells GA, Sigal RJ. Effects of exersice on glycemic control and body mass in type 2 diabetes mellitus. JAMA 2001; 286: 1218-27.
19. Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346: 393-403.
20. Rohfinq CL, Wiedmeyer HM, Little RR, England JD, Tennill A, Goldstein DE. Defining the relationship between plasma glucose and HbA1c: analysis of glucose profiles and HbA1c in the Diabetes Control and Complications Trial. Diabetes Care 2002; 25: 275-8.
21. UK Prospective Diabetes Study (UKPDS). Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes. Lancet 1998; 352: 854-65.
22. Stang M, Wysowski DK, Buttler-Jones D. Incidence of lactic acidosis in metformin users. Diabetes Care 1999; 22: 925-7.
23. AFSSAPS. Traitement médicamenteux du diabète de type 2. Recommandations: texte long, argumentaire. Diabetes Metab 1999; 25 (Suppl. 6): 1-79.
24. ANAES. Stratégie de prise en charge du patient diabétique de type 2 à l'exclusion de la prise en charge des complications. Mars 2000.http://www.anaes.fr
25. Evans JMM, Newton RW, Ruta DA, Mac Donald TM, Stevenson RJ, Morris AD. Frequency of blood glucose monitoring in relotion to glycoemic control: observational study with diabetes database. BMJ 1999; 319: 83-86
26. Blonde L, Ginsberg BH, Horn S et al. Frequency of blood glucose monitoring in relation to glycemic control in patients with type 2 diabetes (letter). Diabetes Core 2002; 25: 245.
27. Schwedes U, Siebolds M, Mertes G, for the SMBG Group. Meal-reloted structured self-monitoring of blood glucose. Effect on diabetes control in non-insulin treated type 2 diabetic patients. Diabetes Care 2002; 25: 1928-32.
28. Guerci B, Drouin P, Grange V et al., for the ASIA Group. Self-monitoring of blood glucose significantly improves metabolic control in patients with type 2 diabetes mellitus: the Auto-Surveillance Intervention Active (ASIA) study. Diabetes Metab 2003; 29: 587-594.
29. UK Prospective Diabetes Study (UKPDS) group. Intensive blood glucose control and sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-53.
30. UKPDS UK Prospective Diabetes Study Group. Tight Blood Pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998; 317: 703-13.
31. Berlowitz DR, Ash AS, Hickey EC, Glickman M, Friedman R, Kader B. Hypertension management in patients with diabetes. The need for more aggressive therapy. Diabetes Care 2003; 26: 355-9.
32. Adler AI, Stratton IM, Neil AW et al., on behalf of the UK Prospective Diabetes Study group. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ 2000; 321: 412-9.
33. Hansson L, Zanchetti A, Carruthers SG et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998; 351: 1755-62.
34. UK Prospective Diabetes Study Group. Efficacity of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. BMJ 1998; 317: 713-20.
35. Heart Outcomes Prevention Evaluation (HOPE) study investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and the MICRO-HOPE study. Lancet 2000; 355: 253-9.
36. Dahlaf B, Dereveux RB, Kjeldsen SE et al., for the LIFE study group. Cardiovascular morbidity and mortality in the losartan intervention for endpoint reduction in hypertension study (LIFE): a randomised trial against atenalol. Lancet 2002; 359: 995-1003.
37. PROGRESS collaborative group. Randomised trial of a perindopril based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischemic attack. Lancet 2001; 358: 1033-41.
38. Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis: epidemiology, pathophysiology and management. JAMA 2002; 287: 2570-81.
39. Pyorala K, Pedersen TR, Kjekshus J, Faergeman O, Olsson AG, Thorgeirsson G, the Scandinavian Simvastatin Survival study (4S) group. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Group. Diabetes Care 1997; 20: 614-20.
40. Heart Protection Study Collaborative group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360: 7-22.
41. Bloomfield Rubins H, Robins SJ, Collins D et al., for the Veterans Affairs High-density lipoprotein cholesterol Intervention Trial Study group. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med 1999; 341: 410-8.
42. Collaborative group of the Primary Prevention Project (PPP). Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general practice. Lancet 2001; 357: 89-95.
43. US Preventive service Task Force. Aspirin for the primary prevention of cardiovascular events: recommendations and rationale. Ann Intern Med 2002; 136: 161-72.
44. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996; 348: 1329-39.
45. Mizock BA. Alterations of fuel metabolism in critical illness: hyperglycemia. Best Pract Res Clin Endocrinol 2001; 15: 533-51.
46. Sala J, Masia R, Gonzales de Molina FJ et al. REGICOR investigators. Short-term mortality of myocardial infarction in patients with diabetes or hyperglycaemia during admission. J Epidemiol Community Health 2002; 56: 707-12.
47. Malmberg K, for the DIGAMI (Diabetes Mellitus, Insulin Glucose Infusion in Acute Myocardial Infarction) study group. Prospective randomised study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus. BMJ 1997; 314: 1512-5.
48. van den Berghe G, Wouters P, Weekers F et al. Intensive insulin therapy in critically ill patients. N Engl J Med 2001; 345: 1359-67.
49. Dandona P, Aljada A, Bandyopadhyay A. The potential therapeutic role of insulin in acute myocardial infarction in patients admitted to intensive care and in those with unspecified hyperglycemia. Diabetes Care 2003; 26: 516-9.
50. Furnary AP, Zerr KJ, Grunkemeier GL, Starr A. Continuous intravenous insulin infusion reduces the incidence of deep sternal wound infection in diabetic patients after cardiac surgical procedures. Ann Thorac Surg 1999; 67: 352-62.
51. Birck R, Krzossok S, Markowetz F, Schnülle P, van der Woude FJ, Braun C. Acetylcysteine for prevention of contrast nephropathy: meta-analysis. Lancet 2003; 362: 598-603.
52. Thomsen HS, Morcos SK, ESUR Contrast Media Safety Committee. Contrast media and metformine: guidelines to disminish the risk of lactic acidosis in non-insulin-dependent diabetics after administration of contrast media. Eur Radiol 1999; 9: 738-40.
53. Diaz-Sandoval JL, Kosowsky BD, Losordo DW. Acetylcysteine to prevent angiography-related renal tissue injury (the APART trial). Am J Cardiol 2002; 89: 356-8.
54. Caputo C, Dokko JH, Durham JH et al. A randomized control trial of N-acetyl cysteine to prevent contrast nephropathy following coronary angiography. Am J Kidney Dis 2002; 39: A14 (abstract).
55. Shindler DM, Kostis JB, Yusuf S et al. Diabetes mellitus a predictar of morbidity and mortality in the studies of left ventricular dysfunction (SOLVD) trial and registry. Am J Cardiol 1996; 39: 1017-20.
56. Blickle JF, Attali JR, Barrou Z et al. Le diabète du sujet âgé. Rapport des experts de l'ALFEDIAM. Diabetes Metab 1999; 25: 84-93.
57. Shorr RI, Ray WA, Daugherty JR, Griffin MR. Incidence and risk factors for serious hypoglycemia in alder persons using insulin or sulfonylureas. Arch Intern Med 1997; 157: 1681-6.
58. Shah BR, Hux JE. Quantifying the risk of infectious diseases for people with diabetes. Diabetes Care 2003; 26: 510-3.
59. Lewis EJ, Hunsicker LG, Clarke WR et al., for the collaborative study group. Renoprotective effect of the Angiotensin-Receptor Antagonist Irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345: 851-60.
60. Brenner BM, Cooper ME, de Zeew D et al., the RENAAL study investigators. Effects of losarton on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861-9.
61. Parving HH, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P. for the Irbesarton in Patients with Type 2 diabetes and Microalbuminuria study group. The effect of Irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345: 870-8.
62. Palmer BF. Renal dysfunction complicating the treatment of hypertension. N Engl J Med 2002; 347: 1256-61.
63. Zanchetti A, Hansson L, Dalhof B et al., on behalf of the HOT study group. Benefit and harm of low-dose aspirin in well-treated hypertensives of different baseline cardiovascular risk. J Hypertension 2002; 20: 2301-7.
64. Adler AL, Stevens RJ, Neil A, Stratton IM, Boulton AJM, Holman RR. for the UK Prospective study. UKPDS 59: hyperqlycemia and other potentially modifiable risk factors for peripheral vascular disease in type 2 diabetes. Diabetes Care 2002; 25: 894-9.
65. Moulik PK, Mtonga R, Gill GV. Amputation and mortality in new-onset diabetic foot ulcers stratified by etiology. Diabetes Care 2003; 26: 491-4.
66. De Sèze J, Leys D. Les accidents vasculaires céré braux chez le diabétique. Sang Thromb Vaiss 1997; 9: 235-40.
67. Davis TME, Millns H, Stratton IM, Holman RR, Turner RC, for the UK Prospective Study Group. Risk factors for stroke in type 2 diabetes. United Kingdom Prospective Diabetes Study (UKPDS) 29. Arch Intern Med 1999; 159: 1097-103.
68. Williams LS, Rotish J, Qi R et al. Effects of admission hyperglycemia on mortality and costs in acute ischemic stroke. Neurology 2002; 59: 67-71.
69. Megherbi SE, Milan C, Minier D et al., European BIOMED Study of Stroke Care Group. Association between diabetes and stroke subtype on survival and functional outcome 3 months after stroke: data from the European BIOMED Stroke Project. Stroke 2003; 34: 688-94.
70. Staessen JA, Fagard R, Thijs L et al., for the Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. Lancet 1997; 350: 757-64.
71. Hansson L, Lindhalm LH, Niskanen L et al., for the Captopril Prevention Project (CAPP) study group. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPP). Lancet 1999; 353: 611-6.
72. Hansson L, Lindholm LH, Ekbom T et al., for the STOP-Hypertension-2 study group. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study. Lancet 1999; 354: 1751-6 (STOP-2).
73. Hansson L, Hedner T, Lund-Johansen P et al., for the NORDIL study group. Randomised trial of effects of calcium antagonists compared with diuretics and β-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study. Lancet 2000; 356: 359-65.
74. Brown MJ, Palmer CR, Castaigne A et al. Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet 2000; 356: 366-72.
75. Svensson P, de Faire U, Sleight P et al. Comparative effects of ramipril on ambulatory and office blood pressures: a HOPE substudy. Hypertension 2001; 38: e28-e32.
76. Lindhom LH, Ibsen HI, Dahlof B et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 1004-10.
77. The ALLHAT officers and coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288: 2981-97.